President Donald Trump has unveiled a sweeping set of tariffs on imported goods. Starting October 1, branded and patented medicines entering the United States will face a 100 percent duty unless companies operate factories in America.
The plan also imposes a 25 percent tariff on heavy-duty trucks and a 50 percent levy on kitchen and bathroom cabinets. Trump presented the measures on Thursday, calling them essential to protect US manufacturers.
On Truth Social, he said a “flood” of imports has harmed domestic producers. He argued the tariffs will support American companies and safeguard jobs.
The announcement comes despite warnings from US businesses that new duties could disrupt supply chains and increase costs.
Pharmaceutical industry reacts
Neil Shearing, chief economist at Capital Economics, said the drug tariffs were less severe than they appeared. He noted exemptions for generic medicines and for companies investing in US production facilities.
He added that many major pharmaceutical companies already operate US plants or plan to expand.
Ireland’s Trade Minister Simon Harris cited the August 21 US-EU agreement, which capped tariffs on European pharmaceutical exports at 15 percent.
United Nations data show Britain exported more than six billion dollars’ worth of medicines to the US last year.
A June trade deal between Washington and London also pledged “preferential treatment outcomes on pharmaceuticals.”
A UK government spokesperson called the announcement concerning and said Britain would continue close engagement with US officials.
UK drugmakers boost US investments
GlaxoSmithKline already operates US facilities. Last week, it pledged 30 billion dollars in research and manufacturing over five years.
AstraZeneca also runs American plants. In July, it announced plans to invest 50 billion dollars in the US by 2030.
William Bain, head of trade policy at the British Chambers of Commerce, said these investments should protect UK companies from new tariffs. He highlighted advanced manufacturing projects already underway.
Several pharmaceutical firms recently withdrew planned investments from Britain, citing difficult conditions.
Jane Sydenham, investment director at Rathbones, said Trump’s trade policies were a key factor. She argued that uncertainty in US trade rules outweighed concerns about Britain’s slower growth.
Tariffs hit trucks and furniture
Trump confirmed a 25 percent duty on heavy-duty trucks. He said the measure would benefit US manufacturers such as Peterbilt and Mack Trucks.
He also announced duties on kitchen and bathroom cabinets and other furniture imports. He said high import volumes were harming domestic producers.
From next week, upholstered furniture will face a 30 percent tariff.
Swedish retailer Ikea said the tariffs make operations more difficult and added that it is monitoring developments closely.
Tariffs remain central to Trump’s trade strategy
Tariffs continue to shape Trump’s second-term economic agenda. In August, sweeping duties on imports from more than 90 countries came into effect. Washington said the measures aim to strengthen US manufacturing and create jobs.
Earlier tariffs targeted steel, copper, aluminium, cars and vehicle components.
The US Chamber of Commerce warned against new duties this year. It noted that most truck parts are imported from Mexico, Canada, Germany, Finland and Japan.
Mexico and Canada supplied more than half of US imports of medium and heavy truck parts last year. The chamber said domestic production was unrealistic and would increase costs.
Experts warn of rising consumer prices
Deborah Elms, trade analyst at the Hinrich Foundation, said the tariffs favour US producers but are “terrible” for consumers. She predicted rising prices across multiple sectors.
She explained that the new measures cover more products and impose higher rates than Trump’s earlier reciprocal tariffs, which aimed to address trade imbalances.
Elms added that industry-specific duties could act as a fallback plan, providing revenue if broader global tariffs face legal challenges.
